The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
Represents one of the largest cell culture biomanufacturing sites in North America, which will employ 1,400 people by 2031
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
ABP-745 is a novel oral therapy with potential applications in cardiovascular and other inflammatory diseases
The study further confirmed that GAL-101 effectively crosses the blood-brain barrier
Nu Nutridac is a nutritional replenisher for neurodegenerative and anxiety-related disorders
The cGMP-4 facility will further strengthen the company's ability to serve global partners
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Subscribe To Our Newsletter & Stay Updated
